Attitudes of psychiatrists toward antipsychotic depot medication

Journal of Clinical Psychiatry

Volumn 67, Issue 12, 2006, Pages 1948-1953

  Heres, Stephan ^a   Hamann, Johannes ^a   Kissling, Werner ^a   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

DEMOGRAPHY; DRUG FORMULATION; EXTRAPYRAMIDAL SYNDROME; HEALTH SURVEY; HUMAN; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 33845998909     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1216     Document Type: Review

References (25)

1. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773
2. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66
3. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003;33:83-89
4. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425
5. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-1589
6. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
7. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-1222
8. Hamann J, Pfeiffer H, Leucht S, et al. Are patients with schizophrenia under-treated with second-generation antipsychotics? a pilot study of the prescription practices of German psychiatrists. Pharmacopsychiatry 2003;36:309-312
9. Hamann J, Langer B, Leucht S, et al. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry 2004;161:1301-1304
10. Kane JM, Leucht S, Carpenter D, et al. Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders. Introduction, methods, commentary, and summary. J Clin Psychiatry 2003;64(suppl 12):5-19
11. Yang YK, Tam YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci 2005;59:385-394
12. Llorca PM, Miadi-Fargier H, Lancon C, et al. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encephale 2005;31:235-246
13. Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005;23:299-314
14. Lam Y, Velligan D, DiCocco M. Comparative assessment of antipsychotic adherence by concentration monitoring, pill count and self-report [abstract]. Schizophrenia Research 2003;60 (suppl 1):313
15. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
16. Byerly M, Fischer R, Rush A. A comparison of clinician vs electronic monitoring of antipsychotic adherence in schizophrenia [poster]. Presented at the 41st annual meeting of the American College of Neuropsychopharmacology; 2002; San Juan, Puerto Rico
17. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247
18. Hamann J, Leucht S, Kissling W. Shared decision making in psychiatry. Acta Psychiatr Scand 2003;107:403-409
19. Bloch Y, Levkovitz Y, Atshuler A, et al. Use of topical application of lidocaine-prilocaine cream to reduce injection-site pain of depot antipsychotics. Psychiatr Serv 2004;55:940-941
20. Lambert T, Brennan A, Castle D, et al. Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract 2003;9:252-260
21. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-307
22. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-299
23. Mentschel C. Depot-drugs may reduce relapse rates in schizophrenic outpatients: a meta-analysis. Presented at the 156th meeting of the American Psychiatric Association, San Francisco, Calif: 2003:71
24. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-108
25. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004;30:255-264